|
½ÃÀ庸°í¼
·ç°Ô¸¯º´ Ä¡·áÁ¦
Lou Gehrig's Disease
|
Global Industry Analysts, Inc. ¿¡¼ 2010³â 04¿ù ¿¡ ¹ßÇàÇÑ ¡¸·ç°Ô¸¯º´ Ä¡·áÁ¦¡¹ º¸°í¼´Â Pages: 258·Î ±¸¼ºµÇ¾î, US $3,450 ºÎÅÍ ±¸¸Å °¡´ÉÇÕ´Ï´Ù.
¼¼°èÀÇ ·ç°Ô¸¯º´(±ÙÀ§Ãà¼ºÃø»ö°æÈÁõ) Ä¡·áÁ¦ ½ÃÀåÀ» Á¶»çºÐ¼®ÇßÀ¸¸ç, º» ÁúȯÀÇ °³¿ä¿Í Ä¡·á¹ý, »õ·Î¿î Ä¡·á¹ýÀ» À§ÇÑ ¿¬±¸°³¹ß µ¿Çâ, Âü¿©±â¾÷ °³¿ä¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù. Á¦1Àå ¼·Ð, Á¶»ç ¹æ¹ý ¹× Á¦Ç° Á¤ÀÇ Á¦2Àå °³¿ä - ¾÷°è °³¿ä
- ¼¼°è ½ÃÀå ºÐ¼®
- Sanofi-Aventis : ±ÙÀ§Ãà¼ºÃø»ö°æÈÁõÀÇ À¯ÀÏÇÑ ¾àÁ¦ Á¦Á¶¾÷ü
- Rilutek
- ±ÙÀ§Ãà¼ºÃø»ö°æÈÁõÀÇ ÀÌȯÀ² ¹× ȯÀÚ¼ö
- ±ÙÀ§Ãà¼ºÃø»ö°æÈÁõ : °³¿ä
- Áß¿ä Á¾·ù
- º´ÀÎ
- ¾ÆÁ÷ ¾Ë·ÁÁöÁö ¾ÊÀº ±ÙÀ§Ãà¼ºÃø»ö°æÈÁõÀÇ Á¤È®ÇÑ ¿øÀÎ
- Áø´Ü
- ±ÙÀ§Ãà¼ºÃø»ö°æÈÁõÀÇ Â¡ÈÄ
- ±ÙÀ§Ãà¼ºÃø»ö°æÈÁõÀÇ ÇØ°áÃ¥
- Ä¡·á¹ý
- ´ëÁõ¿ä¹ý(Symptomatic Treatment)
- ±ÙÀ§Ãà¼ºÃø»ö°æÈÁõÀÇ ÀáÀçÀû Ä¡·á¹ý
- ½Å°æÄ£È¼º ÀÎÀÚ(Neurotrophic Factors)
- ¼ÒºÐÀÚ
- RNA °£¼·
- Áٱ⼼Æ÷°¡ »õ·Î¿î Àü¸Á
- Áٱ⼼Æ÷ ¿¬±¸
- ·ç°Ô¸¯º´ ¸ðµ¨À» ¹ßÀü½ÃŰ´Â LTC
- Çѹæ¿ä¹ý
- ¸®Æ¬
- ±ÙÀ§Ãà¼ºÃø»ö°æÈÁõ À¯ÀüÀÚÇÐ
- ÀÓ»ó½ÃÇè ¹× ¿¬±¸
- ÃÖ±Ù ¾÷°è Ȱµ¿
- Áß¿ä ±â¾÷
- Aeolus Pharmaceuticals, Inc.
- Amorfix Life Sciences Ltd.
- Avicena Group, Inc.
- Ceregene, Inc.
- CytRx Corporation
- Genzyme Corporation
- Isis Pharmaceuticals, Inc.
- Knopp Neurosciences
- Maas Biolab
- NeuroNova AB
- Sygnis Pharma AG
- Teva Pharmaceutical Industries Ltd.
- Trophos SA
- ±ÙÀ§Ãà¼ºÃø»ö°æÈÁõ ºÐ¾ßÀÇ Âü¿© ±â°ü
- ¼¼°è ½ÃÀå Àü¸Á
Á¦3Àå °æÀï Á¤¼¼ - ±â¾÷ °³¿ä : 37°³»ç(ºÎ¼/ÀÚȸ»ç Æ÷ÇÔ 38°³»ç)
ksa
|